Wendie Hopkins

A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

Andrew M. Scott, G. Wiseman, Sydney Welt et al. · PubMed · 2003 · 441 citations

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

Ian D. Davis, Weisan Chen, Heather Jackson et al. · Proceedings of the National Academy of Sciences · 2004 · 437 citations · Full text

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors

Andrew M. Scott, Fook-Thean Lee, Niall C. Tebbutt et al. · Proceedings of the National Academy of Sciences · 2007 · 217 citations · Full text

Immunology, Dermatology, Immunotherapy +16

A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake

Andrew M. Scott, Fook-Thean Lee, Robert H. Jones et al. · Clinical Cancer Research · 2005 · 124 citations · Full text

The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.

Mark Shackleton, Ian D. Davis, Wendie Hopkins et al. · PubMed · 2004 · 123 citations

Immunology, Immunoediting, Adjuvant Flt3 Ligand +18